HCPCS Code Q2053
Brexucabtagene autoleucel, up to 200 million autologous anti-cd19 car positive viable t cells, including leukapheresis and dose preparation procedures, per therapeutic dose
| Short Description | Brexucabtagene car pos t |
|---|---|
| Year | 2026 |
| Coverage Code | C = Carrier judgment |
| Action Code | N = No maintenance for this code |
| Action Effective Date | April 01, 2021 |
| Code Added Date | April 01, 2021 |
| Pricing Indicator | 51 = Drugs |
| Type of Service | 1 = Medical care P = Lump sum purchase of DME, prosthetics, orthotics |